Tweets
RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sjögrens.
⭐️🌱STAR/CRESS response rates also favoured active treatment.
Safe, accessible, affordable option for active disease.
@RheumNow #EULAR2025 #LB0005
Mrinalini Dey @DrMiniDey ( View Tweet )
10 months 1 week ago
Nerandomilast: the new & improved nintedanib.
Does it work for our rheum pts?
Autoimmune subgroup of FIBRONEER-ILD (NEJM last month)
- mortality benefit vs placebo (this is new)
- well tolerated (minimal increase in diarrhoea vs placebo)
One to watch
#EULAR2025 LB0003 @RheumNow https://t.co/u8fIy7kkKW
Links:
David Liew @drdavidliew ( View Tweet )
10 months 1 week ago
FIBRONEER-ILD Ph3 PD4B inhibitor Nerandomilast
1100+ pts, 320+ w/ SARD-ILD wk52
FVC relative reduction of decline 9 mg bid 43% 18 mg bid 39% vs. PBO
HR 0.56 time to first acute exacerbation of ILD, hospitalisation for resp cause or death in higher dose group
11% https://t.co/CeXWB2GlOe
Aurelie Najm @AurelieRheumo ( View Tweet )
10 months 1 week ago
#EULAR2025 Abstr#LB0003 Post-hoc analyses of Phase 3 RCT: Nerandomilast (with or without Nintadenib combo) in sub-group patients with autoimmune #ILD reported similar lung efficacy and safety over PBO, in line with overall trial population. Diarrhoea was common AE @RheumNow https://t.co/fxRdflCi9W
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
10 months 1 week ago
Guselkumab in APEX study (PsA, n=1020, biologic-naïve):
🦴 Less joint damage: 0.55 vs 1.35 (placebo)
💪 More responders: 67–68% hit ACR20 on GUS
🛡 Safety: similar to placebo
GUS - selective IL-23i - delivers joint protection and symptom relief
LB0010 @RheumNow #EULAR2025
Jiha Lee @JihaRheum ( View Tweet )
10 months 1 week ago
Recommendations for RA management at #EULAR2025
- MTX [or other csDMARDs] and steroids still remain the first line- nothing beats that!
- ofcourse minimize steroids!
- rather than stopping meds at remission, reducing doses may be a better solution.
Not much changed.
@RheumNow https://t.co/NK5ejsgjWV
Bella Mehta @bella_mehta ( View Tweet )
10 months 1 week ago
Proud to present the 1st #ARCH_ArLAR prospective interventional study #EULAR2025
Large awareness campaign ➡️
🔺️Proportion new referred CIRDs pts ⬆️ from 31 to 37%
🔺️Time 2 see a rheuma ⬇️ 14 to 10 mo
🔺️Time 2 diagnosis ⬇️ 18 to 12 mo
POS1310
@RheumNow
@ArLARheumatolog https://t.co/eKrRKHNXMZ
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
10 months 1 week ago
In RCT of RA pts in remission/low disease activity, spacing ozoralizumab (next gen TNFi) or reducing MTX led to more flares vs continued tx; but most pts in remission at baseline maintained LDAS.
Remission matters for subsequent Tx reduction.
@RheumNow #EULAR2025 #LB0006
Mrinalini Dey @DrMiniDey ( View Tweet )
10 months 1 week ago
Suppression of inflammation fire 🔥 in #axSpA
may prevent subclinical atherosclerosis progression ❤️
🔺️90 patients
🔺️74% achieved LDA at 12 mo
🔺️Carotid plaque progression was higher in non-LDA group
POS1311
#EULAR2015
@RheumNow
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
10 months 1 week ago
#EULAR2025 Abstr#LB0004 Phase 2 RCT of first-in-class, Enpatoran, TLR7/8-i in active #SLE despite SOC (Cohort B) reported nominal improvement in BICLA but no dose-dependent response. Greater effects seen on active CLE, high IFN-GS or high dose GC. No major safety signal @RheumNow https://t.co/aX4ier0rAy
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
10 months 1 week ago
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.
Dr. John Cush @RheumNow ( View Tweet )
10 months 1 week ago
Enpatoran (TLR7/8 inhibitor) in SLE & CLE
- helps skin, others?
- suppresses interferon
lowest dose was highest response though (upsetting primary endpoint)
Promising, watch for the ph3
No photos allowed, but official slides:
https://t.co/1yX6XrYvKH
#EULAR2025 LB0004 @RheumNow
David Liew @drdavidliew ( View Tweet )
10 months 1 week ago
